Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial

Axicabtagene ciloleucel (axi-cel), a CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy, was the first CAR T-cell therapy approved for the treatment of adu...